Ben A. Hall, Ph.D. assists in prosecuting patents for clients as a technical specialist in a variety of industries, specifically related to biotechnology. His life science-based doctoral and postdoctoral training and multidisciplinary background provide extensive research experience and knowledge in a wide range of areas including molecular biology, oncology, diabetes, biological diagnostic systems, and pharmacology.

Background and Credentials

Prior to joining the firm, Dr. Hall was a research professional at the University of Chicago where he focused on investigating the role of Insulin Receptor Substrate 2 (IRS-2) in novel pancreatic beta cell specific knockout mice models of type II diabetes. Additionally, Dr. Hall was a Chicago Innovation Mentor (CIM) fellow, where he contributed to the scientific development of several local biotechnology start-up companies, and interpreted patents for complex biotechnologies at the University of Chicago Tech Transfer Office. Dr. Hall was also an innovation fund associate for the Chicago Innovation Exchange (CIE) where he contributed to the evaluation of early stage technology including the assessment of the intellectual property and licensing strategies of university-based technologies.

Dr. Hall holds a B.S., with honors, in pharmacology and Ph.D. in Biomedical Sciences from Newcastle University, UK. His graduate studies focused on cell survival signaling pathways in models of skin and melanoma skin cancer. As a postdoctoral research scholar at the University of Chicago, his focus involved identifying the requirement of mTORC1 for SGK1 kinase activation in breast cancer. Dr. Hall also contributed to development of glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Dr. Hall has authored several peer-reviewed articles in the fields of oncology and diabetes research.


  • Newcastle University, UK (Ph.D.)
    • Biomedical Sciences
  • Newcastle University, UK (B.S., with honors)
    • Pharmacology

Publications and Presentations

  • Brickley DR, Agyeman AS, Kopp RF, Hall B A et al. (2013). Serum- and Glucocorticoid-induced Protein Kinase 1 (SGK1) is Regulated by Store-Operated Ca2+ Entry and Mediates Cytoprotection Against Necrotic Cell Death. J Biol Chem. 288 (45).
  • Skor MN, Wonder EL, Kocherginsky M, Goyal A, Hall B A, Cai Y, Conzen SD (2013). Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin Cancer Res. 19 (22)
  • Hall B A, Kim T K, Skor M N, Conzen S D (2012). The requirement for mTORC1 in serum and glucocorticoid-regulated kinase 1 (SGK1) activation correlates with ER-alpha expression. Breast Cancer Res Treat, 135 (2).
  • Gregg B E, Moore P C, Demozay D, Hall B A, Li M, Husain A, Wright A J, Atkinson M A & Rhodes C J (2012). Formation of a Baseline Pancreatic ß-Cell Population in Humans is 1 Set Early in Life. J Clin Endocrinol Metab. 97 (9).
  • Hall B A, Kim T K, Skor M N, Conzen S D. The Role of Estrogen Receptor Signaling in mTORC Activity (2010). Endo Rev. 31 (3).

Click here to see additional Publications and Presentations.

Community and Professional Involvement

  • University of Chicago Biotechnology Association (UCBA), Committee Chair & Editor-in-Chief (2012 –2014)
  • University of Chicago Booth Management Labs Sponsored by AbbVie (2014)
  • Chicago Innovation Fund Associate, Chicago Innovation Exchange (CIE) (2013 –2014)
  • Chicago Innovation Mentors (CIM) fellow (2013- 2015)
  • Member of the Chicago Innovation Exchange
  • Member of Chicago Innovation Mentors